Servicio de Nefrología, Departamento de Pediatría, Hospital Humberto Notti, Mendoza, Argentina.
Instituto de Medicina y Biología Experimental de Cuyo (IMBECU), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Mendoza, Argentina.
Pediatr Nephrol. 2021 Jun;36(6):1499-1509. doi: 10.1007/s00467-020-04829-4. Epub 2020 Nov 17.
Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome (STEC-HUS) is the main cause of pediatric acute kidney injury (AKI) in Argentina. Endothelial injury is the trigger event in the microangiopathic process. The host inflammatory response to toxin and E. coli lipopolysaccharide (LPS) is involved in disease pathophysiology.
This retrospective study describes pediatric STEC-HUS patients with multiorgan involvement at the initial phase of disease. A retrospective study of critically ill HUS patients with evidence of E. coli infection was conducted through a period of 15 years.
Forty-four patients 35.4 ± 4.1 months were admitted to the intensive care unit for 21 ± 2 days. Mechanical ventilation was required in 41 patients, early inotropic support in 37, and 28 developed septic shock. Forty-one patients required kidney replacement therapy for 12 ± 1 days. Forty-one patients showed neurological dysfunction. Dilated cardiomyopathy was demonstrated in 3 patients, left ventricular systolic dysfunction in 4, and hypertension in 17. Four patients had pulmonary hemorrhage, and acute respiratory distress syndrome in 2. Colectomy for transmural colonic necrosis was performed in 3 patients. Thirty-seven patients were treated with therapeutic plasma exchange, and 28 patients received methylprednisolone (10 mg/kg for 3 days). Of the surviving 32 patients, neurological sequelae were seen in 11 and chronic kidney failure in 5.
Severe clinical outcome at onset suggests an amplified inflammatory response after exposure to Shiga toxin and/or E. coli LPS. STEC-HUS associated with severe neurological involvement, hemodynamic instability, and AKI requires intensive care and focused therapy.
产志贺样毒素大肠杆菌相关性溶血尿毒症综合征(STEC-HUS)是阿根廷儿童急性肾损伤(AKI)的主要病因。内皮损伤是微血管病过程中的触发事件。宿主对毒素和大肠杆菌脂多糖(LPS)的炎症反应参与了疾病的病理生理过程。
本回顾性研究描述了疾病初始阶段有多器官受累的儿科 STEC-HUS 患者。通过 15 年的时间,对有大肠杆菌感染证据的危重症 HUS 患者进行了回顾性研究。
44 例患者(35.4±4.1 个月)入住重症监护病房 21±2 天。41 例患者需要机械通气,37 例患者需要早期正性肌力支持,28 例患者发生感染性休克。41 例患者需要肾脏替代治疗 12±1 天。41 例患者出现神经系统功能障碍。3 例患者出现扩张型心肌病,4 例患者出现左心室收缩功能障碍,17 例患者出现高血压。4 例患者出现肺出血,2 例患者出现急性呼吸窘迫综合征。3 例患者因全层结肠坏死而行结肠切除术。37 例患者接受了治疗性血浆置换,28 例患者接受了甲基强的松龙(10mg/kg,连用 3 天)治疗。在 32 例存活患者中,11 例出现神经系统后遗症,5 例出现慢性肾衰竭。
发病时严重的临床结局提示在接触志贺样毒素和/或大肠杆菌 LPS 后炎症反应放大。与严重神经受累、血流动力学不稳定和 AKI 相关的 STEC-HUS 需要重症监护和针对性治疗。